HGENQ — Humanigen Share News
0.000.00%
Last trade - 00:00- $0.00m
- -$3.10m
- $2.51m
Humanigen up on deal to make COVID-19 drug with French firm
Brief: Humanigen And Cenexi Announce Collaboration To Manufacture Lenzilumab In France
Brief: Humanigen Aligns With FDA On Potential Registration Phase 3 Study For Lenzilumab With CAR-T
Brief: Humanigen Announces Target Enrollment in Phase 2/3 Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved
Brief: Humanigen Inc - Met With Senior Staff Of FDA In A Type B Meeting Regarding Lenzilumab For The Treatment Of COVID-19
U.S. STOCKS ON THE MOVE-Snowflake, Tantech, Kroger, C3.ai
U.S. STOCKS ON THE MOVE-Apple, CF Acquisition, Tantech, MEI Pharma
Humanigen jumps on positive results for key drug
Humanigen Inc reports results for the quarter ended in September - Earnings Summary
U.S. STOCKS ON THE MOVE-Oscar Health, Paysafe, Bumble
U.S. STOCKS ON THE MOVE-Affirm, Rivian, Bright Health
Humanigen up on trial tie-up in UK for graft-vs-host disease drug
Brief: Humanigen Says First Patient Dosed In Phase 2 Precision Medicine Study Of Lenzilumab In Patients With Chronic Myelomonocytic Leukemia
Brief: Humanigen Inc Announces Preparation Of Phase 1B Study OF IFABOTUZUMAB In Solid Tumors
Brief: Humanigen Inc Board Increased Size Of Board From Five To Seven Members
Brief: Humanigen Announces Late-Breaking Presentation At The Chest Annual Meeting Highlighting C-Reactive Protein As A Biomarker For Identifying Patients Most Likely To Benefit From Treatment With Lenzilumab
Refinitiv Newscasts - U.S. Morning Call: Jobs, Chubb, Cigna, Oil, Ready to balloon to the edge of Space?
Humanigen rises on deal enabling access to its COVID-19 drug
Brief: Humanigen Signs Contract With Clinigen For Lenzilumab Managed Access Program In Europe